0000950170-24-045142.txt : 20240417 0000950170-24-045142.hdr.sgml : 20240417 20240417163602 ACCESSION NUMBER: 0000950170-24-045142 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240415 FILED AS OF DATE: 20240417 DATE AS OF CHANGE: 20240417 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Pizzuti Dana CENTRAL INDEX KEY: 0001948238 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38583 FILM NUMBER: 24851581 MAIL ADDRESS: STREET 1: C/O CRINETICS PHARMACEUTICALS, INC. STREET 2: 10222 BARNES CANYON ROAD, BUILDING 2 CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Crinetics Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001658247 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 263744114 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 10222 BARNES CANYON ROAD, BLDG. #2 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-450-6464 MAIL ADDRESS: STREET 1: 10222 BARNES CANYON ROAD, BLDG. #2 CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 ownership.xml 4 X0508 4 2024-04-15 false 0001658247 Crinetics Pharmaceuticals, Inc. CRNX 0001948238 Pizzuti Dana C/O CRINETICS PHARMACEUTICALS, INC. 6055 LUSK BOULEVARD SAN DIEGO CA 92121 false true false false Chief Med and Dev Officer true Common Stock 2024-04-15 4 M false 14375 16.89 A 42161 D Common Stock 2024-04-15 4 S false 14375 44.47 D 27786 D Stock option (Right to Buy) 16.89 2024-04-15 4 M false 14375 0 D 2032-10-10 Common Stock 14375 177292 D The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $44.47 per share. The range of sales prices on the transaction date was $43.98 to $44.75 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request. The option is exercisable as follows: 25% of the shares subject to the option vest on September 30, 2023, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal monthly installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Marc Wilson, as attorney-in-fact 2024-04-17